SPEEDEL BIO
Speedel Bio engaged in Research and development of law, economics and social sciences.
SPEEDEL BIO
Industry:
Law Enforcement Market Research
Founded:
2003-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Status:
Active
Similar Organizations
Agerus
Agerus is a research and development company that offers work-life research and scientific theories.
JA
JA engages in research and development of information processing systems.
Microbial Technics
Microbial Technics engages in the research and development in the natural sciences and engineering.
More informations about "Speedel Bio"
Speedel Pharma AG - Drug pipelines, Patents, Clinical trials
Explore Speedel Pharma AG with its drug pipeline, therapeutic area, technology platform, 7 clinical trials, and 2 literature, Drug:Avosentan, SPP-635.See details»
Organization | Speedel Pharma Ltd. - Purdue University
Speedel Pharma Ltd. Report issue. For profit Phase 2 Phase 3. Founded: Basel Switzerland ... Organization Overview. First Clinical Trial. 2003 NCT00074620. First Marketed Drug. None ...See details»
Speedel AG - Drug pipelines, Patents, Clinical trials - Synapse
Last update 01 Nov 2024. Speedel AG. Private CompanySee details»
The Speedel Group - Drug pipelines, Patents, Clinical trials - Synapse
Explore The Speedel Group with its drug pipeline, therapeutic area, technology platform, , Drug:SPP-635, SPP-2645, SPP-676.See details»
Speedel Bio - Crunchbase
Speedel Bio engaged in Research and development of law, economics and social sciences.See details»
Novartis to buy biotech firm for SFr900m - Financial Times
Jul 10, 2008 We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to …See details»
Speedel - Basel, Switzerland - bionity.com
Apr 3, 2008 Speedel welcomed the announcement that Speedel and Novartis have won the overall Gold Award in the seventh annual Wall Street Journal contest for ... Read news . 18 …See details»
Andrin Oswald, pharmaceutical executive | World Biographical
Create Biography General ... Chief Executive Officer Speedel Holding AG (acquired by Novartis AG). Chief Executive Officer, ... Assistant to chairman & Chief Executive Officer, head, country …See details»
Speedel - Products, Competitors, Financials, Employees, …
Use the CB Insights Platform to explore Speedel's full profile. Speedel - Products, Competitors, Financials, Employees, Headquarters Locations Technology VendorsSee details»
Speedel - Company Profile - Tracxn
Speedel - Develops renin inhibitors for the treatment of cardiovascular and metabolic diseases. Acquired by Novartis. Raised a total funding of $100M over 3 rounds from 1 investor. Speedel …See details»
Speedel Pharma - PitchBook
Speedel Pharma was founded in 1998. Where is Speedel Pharma headquartered? Speedel Pharma is headquartered in Basel, Switzerland. What is the size of Speedel Pharma? Speedel …See details»
Speedel Brings In CHF47.8M To Advance Pipeline Projects
Feb 23, 2005 Speedel initially built up a pipeline by in-licensing projects from big pharma partners, taking them through early clinical development and then licensing them back out …See details»
Novartis buying Speedel for $880 million - Fierce Biotech
Jul 10, 2008 While Speedel--a 2005 Fierce 15 company--has recently reported several development setbacks, Novartis also gains a pipeline of experimental therapies that includes …See details»
Speedel Experimenta Ltd - Drug pipelines, Patents, Clinical trials ...
Nov 1, 2024 Explore Speedel Experimenta Ltd with its drug pipeline, therapeutic area, technology platform, , Technology Platform:Small molecule drug, Drug:Avosentan. ... The …See details»
Speedel Holding - Products, Competitors, Financials, Employees ...
Speedel to list without IPO - European Biotechnology News. May 18, 2016. Speedel to list without IPO 28.09.2005 Basel - In keeping with its habit of doing things differently, Speedel Holding …See details»
Speedel Receives Major Development Milestones From Novartis
Jul 14, 2004 Speedel developed SPP100 through phase I and II in 18 clinical studies comprising about 500 patients and healthy volunteers before Novartis licensed the compound in 2002. …See details»
Speedel raises $56M for drug development work | Fierce Biotech
Aug 3, 2005 Switzerland's Speedel has raised $56 million through a convertible loan program. The company plans to put the money to use for its drug development work, including a Phase …See details»
SPP-2645 - Drug Targets, Indications, Patents - Synapse - Patsnap
SPP-2645: a Aldosterone antagonists Drug, Initially developed by The Speedel Group, Now, its global highest R&D status is Pending, Mechanism: Aldosterone antagonists, Therapeutic …See details»
SPP-635 - Drug Targets, Indications, Patents - Synapse - Patsnap
Speedel Pharma AG EUCTR2006-004176-13-DE / Not yet recruiting Not Applicable A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Parallel-Design, Four-week Study to …See details»